Related Experiment Videos

Mutagenicity studies with N6, O2'-dibutyryl cyclic adenosine 3',5'-monophosphate (DBcAMP)

H Shimada1, Y Ebine

  • 1Research Institute, Daiichi Seiyaku Co., Ltd., Tokyo, Japan.

Mutation Research
|September 1, 1987
PubMed

Insights

N6,O2'-Dibutyryl cyclic adenosine 3,5-monophosphate (DBcAMP) showed no mutagenic effects in bacterial assays. Cytogenetic studies also indicated no mutagenicity, suggesting DBcAMP is safe from a genetic mutation perspective.

Area of Science:

  • Toxicology
  • Molecular Biology
  • Genetics

Background:

  • N6,O2 -Dibutyryl cyclic adenosine 3,5-monophosphate (DBcAMP) is a cAMP analog.
  • Assessing the mutagenic potential of chemical compounds is crucial for safety evaluations.

Purpose of the Study:

  • To evaluate the mutagenicity of DBcAMP using multiple standard assays.
  • To determine if DBcAMP poses a risk for genetic mutations.

Main Methods:

  • Rec assay using Bacillus subtilis.
  • Ames test with Salmonella typhimurium strains (TA1535, TA1537, TA1538, TA98, TA100) and Escherichia coli (WP2 uvrA).
  • In vitro cytogenetic study to assess chromosomal aberrations.

Main Results:

  • DBcAMP demonstrated no mutagenic activity in the rec assay.
  • No mutagenic effects were observed in the Ames test across all bacterial strains.
  • A high concentration in the cytogenetic study showed chromosomal aberrations, likely due to osmotic pressure, not direct mutagenicity.

Conclusions:

  • DBcAMP does not exhibit mutagenic potential based on the conducted assays.
  • The compound is considered safe regarding genetic mutations.
  • The observed chromosomal aberrations were attributed to experimental conditions rather than inherent mutagenicity.

Related Concept Videos